Dexrazoxane Protects Cardiomyocyte from Doxorubicin-Induced Apoptosis by Modulating miR-17-5p

The usage of doxorubicin is hampered by its life-threatening cardiotoxicity in clinical practice. Dexrazoxane is the only cardioprotective medicine approved by the FDA for preventing doxorubicin-induced cardiac toxicity. Nevertheless, the mechanism of dexrazoxane is incompletely understood. The aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Xiaoxue, Ruan, Yang, Shen, Tao, Qiu, Quan, Yan, Mingjing, Sun, Shenghui, Dou, Lin, Huang, Xiuqing, Wang, Que, Zhang, Xiyue, Man, Yong, Tang, Weiqing, Jin, Zening, Li, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071803/
https://www.ncbi.nlm.nih.gov/pubmed/32190669
http://dx.doi.org/10.1155/2020/5107193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071803/
https://www.ncbi.nlm.nih.gov/pubmed/32190669
http://dx.doi.org/10.1155/2020/5107193

Ejemplares similares